



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2017/059481
- (22) **International Filing Date:**
01 November 2017 (01.11.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/416,602 02 November 2016 (02.11.2016) US
- (71) **Applicant: JOUNCE THERAPEUTICS, INC.** [US/US];
780 Memorial Drive, Cambridge, Massachusetts 02139 (US).
- (72) **Inventors: MABRY, George Robert, III;** 780 Memorial Drive, Cambridge, Massachusetts 02139 (US).
SAZINSKY, Stephen; 780 Memorial Drive, Cambridge, Massachusetts 02139 (US).
- (74) **Agent: SCARR, Rebecca B.** et al.; McNeill Baur PLLC, 500 W. Silver Spring Drive, Suite K-200, Glendale, Wisconsin 53217 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,


DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

- (54) **Title:** ANTIBODIES TO PD-1 AND USES THEREOF

**FIG. 5**

- (57) **Abstract:** Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.